These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9093260)

  • 21. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
    Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
    Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
    [No Abstract]   [Full Text] [Related]  

  • 22. Indinavir nephropathy.
    Tashima KT; Horowitz JD; Rosen S
    N Engl J Med; 1997 Jan; 336(2):138-40. PubMed ID: 8992346
    [No Abstract]   [Full Text] [Related]  

  • 23. Indirect hyperbilirubinemia with indinavir.
    Satija P; Parikh F; Aggarwal V; Sharma B; Hakim A; Pai-Dhungat JV
    J Assoc Physicians India; 2002 Oct; 50():1316-7. PubMed ID: 12568221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patients failing saquinavir therapy require an early change to indinavir before HIV-1 viral load reaches high levels.
    Dronda F; Pérez-Elías MJ; Antela A; Casado JL; Martí-Belda P; Cobo J
    Antivir Ther; 1999; 4(2):117-21. PubMed ID: 10682157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)].
    Tanon AK; Eholié SP; Polneau S; Kra O; Ello F; Ehui E; Aoussi E; Djadji A; Kakou A; Bissagnéné E; Kadio A
    Med Mal Infect; 2008 May; 38(5):264-9. PubMed ID: 18395375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone.
    Kelly DV; Béïque LC; Bowmer MI
    Ann Pharmacother; 2002 May; 36(5):827-30. PubMed ID: 11978161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus-co-infected patient starting antiretroviral triple combination therapy.
    Karras A; Rabian C; Zylberberg H; Hermine O; Duchatelle V; Durand F; Valla D; Viard JP
    AIDS; 1998 May; 12(7):827-9. PubMed ID: 9619823
    [No Abstract]   [Full Text] [Related]  

  • 28. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
    Wasmuth JC; Rodermann E; Voigt E; Vogel M; Lauenroth-Mai E; Jessen A; Burger D; Rockstroh JK
    Eur J Med Res; 2007 Jul; 12(7):289-94. PubMed ID: 17933700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results on new AIDS drugs bring cautious optimism.
    Cohen J
    Science; 1996 Feb; 271(5250):755-6. PubMed ID: 8628987
    [No Abstract]   [Full Text] [Related]  

  • 31. Merck protease inhibitor available to persons with CD4 count 50 or less--must register by August 11.
    AIDS Treat News; 1995 Jul; (no 227):1-2. PubMed ID: 11362618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-2 continues to show promise as HIV therapy.
    NIAID AIDS Agenda; 1996 Sep; ():2. PubMed ID: 11363922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protease inhibitor approved for AIDS treatment.
    AORN J; 1996 Sep; 64(3):453. PubMed ID: 8876926
    [No Abstract]   [Full Text] [Related]  

  • 36. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor.
    Murphy M; Armstrong D; Sepkowitz KA; Ahkami RN; Myskowski PL
    AIDS; 1997 Feb; 11(2):261-2. PubMed ID: 9030382
    [No Abstract]   [Full Text] [Related]  

  • 37. Indinavir-associated toxicity mimicking urinary tuberculosis in a patient with AIDS.
    Delfino VD; Santiago NM; Mocelin AJ; Kunii LF; Bortoliero AL
    Braz J Infect Dis; 2008 Feb; 12(1):99-100. PubMed ID: 18553024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Undetectable HIV levels after triple therapy with indinavir.
    AIDS Patient Care STDS; 1997 Jun; 11(3):193-4. PubMed ID: 11361795
    [No Abstract]   [Full Text] [Related]  

  • 39. [Granular lymphocyte-proliferative disorder following initiation of protease inhibitor therapy in a patient with acquired immunodeficiency syndrome].
    Tanaka K; Honda J; Shiraishi K; Jojima H; Tanaka M; Okubo Y; Fukahori S; Fujimatsu Y; Oizumi K
    Kansenshogaku Zasshi; 1999 Jul; 73(7):702-6. PubMed ID: 10481407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS.
    Chougnet C; Jankelevich S; Fowke K; Liewehr D; Steinberg SM; Mueller BU; Pizzo PA; Yarchoan R; Shearer GM
    J Infect Dis; 2001 Jul; 184(2):201-5. PubMed ID: 11424019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.